PDS Biotechnology (PDSB)

• Market cap: $60.6M
• 1 day: 9.24%
• 5 days: 5.69%
• 1 month: 10.17%
• 3 months: -9.09%
• 6 months: 3.17%
• Year to date: -24.86%
• 1 year: -59.12%
• 5 years: -52.55%
• 10 years: -99.50%
• Sector: Healthcare
• Industry: Biotechnology

About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Employees: 24

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

13% more funds holding

Funds holding: 47 [Q1] → 53 (+6) [Q2]

0% more capital invested

Capital invested by funds: $9.79M [Q1] → $9.83M (+$39.9K) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

1.96% less ownership

Funds ownership: 18.12% [Q1] → 16.16% (-1.96%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 900% upside
• Avg. target: $13 900% upside
• High target: $13 900% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis

900% upside $13

Buy Reiterated

1 Jul 2025